Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.
— Nephrology Journal Club (@NephJC) January 20, 2023
Up first is NefIgArd.
We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?
IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP